Electroporation has been shown to significantly increase plasmid transfer to the skeletal muscle, but this procedure is also implicated in muscle damage. We are reporting a highly efficient in vivo transfer of a plasmid formulated with poly-(L-glutamate) (PLG) into murine, canine and porcine muscle fibers using electric pulses of low field intensity. In mice and pigs, the use of secreted embryonic alkaline phosphatase (SEAP) as the indicator gene caused increased PLG expression by 2-3 fold compared to naked plasmid; while delivery of a PLG-plasmid formulation to dogs showed a 10-fold increase in serum SEAP levels compared to plasmid alone. Muscle lesions were reduced by the protective PLG. Thus, PLG may constitute a useful adjuvant for increased expression and reduced muscle trauma to plasmid DNA delivered by electroporation.
Introduction
An ideal delivery system for in vivo gene transfer should be simple, safe and provide prolonged expression of transgenes at therapeutic levels. Plasmid constructs are attractive candidates for direct injection into skeletal muscle because plasmids are well-defined entities that are biochemically stable and have been used successfully for many years (1, 2) . In a few cases, the relatively low expression levels achieved after simple plasmid injection, are sufficient to reach physiologically acceptable levels of bioactivity of secreted peptides (3, 4) .
Recently, significant progress has been obtained using electroporation to enhance plasmid delivery in vivo. Electroporation has been used very successfully to transfect tumor cells after injection of plasmid (5, 6) or to deliver the anti-tumor drug bleomycin to cutaneous and subcutaneous tumors in humans (7, 8) . Electroporation also has been extensively used in mice (9-11), rats (12, 13) , and dogs (14) to deliver therapeutic genes that encode for a variety of hormones, cytokines or enzymes. Our previous studies using growth hormone releasing hormone (GHRH) showed that plasmid therapy with electroporation is scalable and represents a promising approach to induce production and secretion of proteins in large animals and humans (15, 16) .
Despite the recent advances in the technology of plasmid transfer, additional improvements in electroporation techniques and plasmid formulations are needed. For example, in theory, the entire electroporation procedure can be completed without causing permanent damage to the cell. However, in some instances, electroporation procedures impinge on fatal stress for some skeletal muscle cells (14, 17) as well as promote the degradation of the plasmid (18).
We report a plasmid formulation that enhances expression in and prevents excessive cellular damage of muscle cells during the electroporation procedure. Our strategy uses low concentrations of the transfection-facilitating anionic polymer sodium poly-(L-glutamate) (PLG) of low molecular weight. The efficiency of the electrokinetic delivery of a plasmid was demonstrated in the skeletal muscle of three different mammalian species. The electrodes used in these experiments were adapted to each species: for mice, external plate electrodes, and for dogs and pigs, internal needle electrodes, while maintaining similar optimized electroporation conditions.
Material and Methods

DNA Constructs
Plasmid vectors that contain the muscle-specific synthetic promoter SPc5-12 have been previously described (19) . The pSP-SEAP construct contains the SacI/HindIII SPc5-12 fragment, and the SEAP gene followed by the SV40 3'UTR from pSEAP-2 Basic Vector (Clontech Laboratories, Inc., Palo Alto, CA). The pSP-Luc vector contains the same SPc5-12 muscle specific promoter inserted into the SacI/HindIII sites of pGL-2 basic vector (Promega, Madison, WI, USA).
Electroporation Conditions
Square wave pulses were used in all experiments. Electroporation was conducted as follows: 25-250 V/cm, 6 pulses for mice or 5 pulses for pigs and dogs, at 50 milliseconds/pulse, with 1 second between pulses. Caliper (BTX, division of Genetronics Inc., San Diego, CA) and needle electrodes were used to deliver in vivo electric pulses. The plate (caliper) electrodes consisted of 1.5 cm square metallic blocks mounted on a ruler, so the distance between the plates could be easily assessed; the 5-needle device consisted of a circular array (1 cm diameter) of five equally spaced 21gauge needles, mounted on a non-conductive material. All needles were 2 cm in length. Needles were activated sequentially, for every pulse, 3 of 5 needles are activated, with one negative and two positives. In all injections, the entire length of needles was completely inserted into the skeletal muscle.
Intramuscular Injection of Plasmid DNA in Adult Mice
Plasmid preparations of pSP-Luc and pSP-SEAP were diluted in water to 1 mg/mL. ICR male mice (Harlen Laboratories, Houston, TX), 5-6 weeks old, were anesthetized with an intraperitoneal injection 0.5 mL/kg of a combination of ketamine (42.8 mg/mL), xylazine (8.2 mg/mL) and acepromazine (0.7 mg/mL). For the luciferase experiments, the specific plasmid quantity for each experimental group was diluted into a final volume of 25 µL sterile water and injected into the tibialis anterior. Injection was followed by electro-poration within 2 minutes. At 1 week after the injection, the injected muscle and contralateral muscle (as control) were snap frozen in liquid nitrogen. Muscles were homogenized in phosphate buffered saline, pH 7.4, containing 0.2% Triton-100 and protease inhibitors: leupeptin, 0.7 µg/mL, pepstatin 10 µg/mL and aprotinin 2 µg/mL (Boehringer Mannheim, Indianapolis, IN). Muscle extracts were centrifuged at 10,000 x g for 30 minutes at 4º C and the supernatant recovered. Protein assays were performed using Bio-Rad Protein Assay (Bio-Rad Laboratories, Hercules, CA) and luciferase activity was measured. For the SEAP experiments, ten micrograms of plasmid in 25 µL sterile water or increasing dilutions (0.01 -6 mg/mL) of sodium salt of PLG (MW=10.5 kDa average) (Sigma, St.Louis, MO) were injected directly into the anterior tibialis of mice. Mice were bled 7 days post-injection and serum was used for the specific assay. For each condition, six to fifteen animals were used. The experiments were repeated twice. Animals were maintained in accordance with NIH, USDA and Animal Welfare Act guidelines and approved by the Baylor College of Medicine Institutional Animal Care and Use Committee (IACUC).
Intramuscular Injection of Plasmid DNA in Pigs
Three month-old hybrid barrows (PIC -Berkeley, CA), 60-75 kg in weight, were used in the SEAP studies (n=3/group/experiment). Experiments were repeated twice. The animals were suckled for the first 21 days and after weaning were individually housed with ad libitum access to water. Pigs were fed a 24% protein diet (Producers Cooperative Association, Bryan, TX). The animals were weighed every time they were bled, at 8:30 AM. Endotoxinfree plasmid (Qiagen Inc., Chatsworth, CA, USA) preparations were diluted in sterile water. Naked plasmid pSP-SEAP or a 0.01mg/mL PLG-plasmid sterile solution was injected through the intact skin into the sternocranialis muscle using a 21-gauge needle. Two minutes later, electrodes (5-needle array) were inserted into the injected muscle, and 5 pulses of 200V/cm at 50 milliseconds/pulse were applied. Blood was collected by jugular vein puncture before plasmid injection and at 3, 7, 14 and 21 days post-injection and centrifuged at 5000 x g for 10 minutes. The supernatant was stored at -80º C until further analysis.
Intramuscular Injection of Plasmid DNA in Dogs
Twenty Beagle dogs (Harlan, Indianapolis, IN) were individually housed and maintained at Stillmeadow, Inc. (Sugarland, TX) in accordance to the IACUC regulations. The animals were enrolled in a survival protocol and were not killed at the end of the experiment. Groups of five dogs were anesthetized with intravenous injection of Propofol (Abbott Laboratories, IL 4-8 mg/kg) and injected with plasmid pSP-SEAP (0.1 or 0.5 mg), alone or in a 0.01 mg/mL PLG solution directly into the semitendinosus muscle, using a 3/10 cc insulin syringe and a 29 gauge 1/2′′ needle (Becton-Dickinson, Franklin Lakes, NJ). Two minutes after injection, the injected muscle was electroporated (5 pulses, 150V/cm at 50 milliseconds/pulse). Animals were allowed to recover for several hours before being returned to their housing facility. Dogs were weighed and bled prior to injection and at days 3, 6 and 10 post-injection. Serum was stored at -80º C until assayed.
Secreted Embryonic Alkaline Phosphatase Assay
Animals were weighed and bled at the time of plasmid injection (Day 1, time 0), as well as at all indicated time points. SEAP was measured in serum with Phospha-Light Chemiluminescent Reporter Assay Kit (Tropix, Bedford, MA) per manufacturer instructions.
Histological Analysis of Mouse Muscle
Tibialis anterior biopsy samples of the injection site were fixed immediately after dissection in 10% buffered formalin in PBS. After overnight fixation, samples were washed and stored in 70% ethanol until analyzed. Muscle tissue was embedded in paraffin, and five micron-thick sections were cut, deparaffinized, and washed in PBS. Sections were stained with hematoxylin/eosin to visualize tissue morphology. For each animal, at least five fields were analyzed; the analyzer was blinded to experimental grouping. Three animals per group were analyzed. Digital images of the slides were captured using a CoolSnap digital color camera (Roper Scientific, Tucson, AZ) with MetaMorph software (Universal Imaging Corporation, Downington, PA) and a Zeiss Axioplan 2 microscope with a 10x objective.
Statistics
Data were analyzed using STATISTICA analysis package (StatSoft, Inc. Tulsa, OK). Values shown in the figures are the mean ± standard error of the mean. Specific values were obtained by comparison using Student's T-test and ANOVA. A value of p<0.05 was set as the level of statistical significance.
Results and Discussion
Dose-and Voltage-dependent Transgene Expression in Adult Mice
Direct intra-muscular plasmid injection followed by electroporation is a method for the local and controlled delivery of plasmid into skeletal muscle. In our initial experiments we delivered by caliper electrodes pulses of 200V/cm, a parameter previously described (20) . Increasing amounts of muscle specific expression plasmids (19) for luciferase were injected and electroporated into the tibialis anterior muscle of adult mice (n = 6-10/group/experiment). Luciferase levels were measured 7 days post treatment and found to be elevated in a dose-dependent manner for all muscle-specific constructs ( Figure 1A) . Linear regression analysis showed proportional increase in transgene expression over the range of plasmid dose examined (7.5-30 µg) for all constructs (R=0.97 for the skeletal alpha-actin, R=0.987 for the SPc1-28 and R=0.994 for the SPc5-12 promoter, respectively). For subsequent experiments, the construct driven by the SPc5-12 synthetic promoter was used. With the use of an intermediate dose of 15 µg pSP-Luc plasmid, luciferase expression increased with the field strength from 0-250V/cm (R=0.996), but declined at field strength above this range ( Figure 1B) . At voltage conditions of 250V/cm, 6 pulses, 50 milliseconds/pulse, luciferase expression was increased up to 22 fold compared to plasmid injection without electroporation (480±158 versus 22±3.2 RU/µg protein, p<0.05).
Poly-(L-glutamate) Formulated Plasmid Electroporation 367
Technology Luciferase expression in the tibialis anterior muscle of adult mice (n=6-10/group/experiment, for a total of 12-20 animals for each condition) increased linearly with plasmid dosage using different muscle specific constructs: synthetic promoter SPc1-28, synthetic promoter SPc5-12, and skeletal alpha-actin SP448 promoter. B. Luciferase expression increased proportionally with increased voltage up to 250V/cm in mice injected with a pSPc5-12-Luc construct and electroporated. Graphs depict mean values for the total number of animals included in experiments ± standard error of the mean. No EP, group of mice plasmid injected, but not electroporated; 25V/cm -400V/cm, groups of mice plasmid injected and electroporated using the specified voltage conditions; PBS, group of mice injected with PBS and electroporated at 200V/cm. Histological examination of injected muscles revealed areas of damage at 200-250V/cm (Figure 2A-C) , with heat damage, areas of scar tissue, and regeneration. These changes were not present when lower voltage conditions were used ( Figure 2D ).
Poly-L-glutamate Enhances Plasmid Expression in Mice
Following the same electroporation procedure, we tested the hypothesis that the anionic polymer sodium PLG could enhance plasmid uptake at low plasmid concentrations, while reducing any possible tissue damage caused by the procedure. The ability of electroporation to enhance plasmid uptake into the skeletal muscle has been well documented, as previously described. PLG is a stable compound and resistant to relatively high temperatures (21). PLG has been previously used to increase stability in vaccine preparations (22) without increasing their immunogenicity. It also has been used as an anti-toxin post-antigen inhalation or exposure to ozone (23). In addition, plasmid formulated with PLG or polyvinylpyrrolidone (PVP) has been observed to increase gene transfection and consequently gene expression to up to 10 fold in the skeletal muscle of mice, rats and dogs (14, 24) . PLG has been used to increase stability of anti-cancer drugs (25) and as "glue" to close wounds or to prevent bleeding from tissues during wound and tissue repair (26, 27) .
Two separate sets of experiments were conducted in mice (n= 15/group). All mice were given a total of 30 µg pSP-SEAP +/-PLG (weighted average MW= 10,900) in a total volume of 25 µL. Plasmid injection was followed by electroporation (150V/cm) in all cases. One group of mice received naked, non-coated plasmid; the subsequent groups received plasmid coated with decreasing concentrations of PLG: 6, 1, 0.1 and 0.01 mg/mL. Mice were bled and serum was collected and assayed for SEAP. Although naked plasmid (Figure 3) showed some expression, all groups with the nucleic acid expression vector associated with PLG showed significantly higher serum levels of SEAP (p<0.05). When muscle samples from animals from each group were analyzed histologically, mice that received the SEAP construct coated with 0.01 mg/mL PLG had the least inflammation associated with the delivery procedure at 3 days post-injection. Despite higher expression, mice injected with plasmid formulated with 6 mg/mL PLG had increased inflammation and some morphological changes. This observation correlates with the data in the literature, which show short-term enhanced expression using PLG compounds and expression that disappears at approximately 1 month post-injection (14). We determined that a mol/mol ratio of DNA phosphate groups to PLG carboxyl groups is the optimum concentration for therapeutic applications to the skeletal muscle that results in increased expression of the transgene with no damage to the target tissue.
Poly-L-glutamate Enhances Plasmid Expression in Large Mammals -Pigs and Dogs
It has been shown that the degree of permeabilization of the muscle cells is dependent upon the electric field intensity, length of pulses, shape and type of electrodes (28), and cell size (29). Electrode configuration, plates (16, 18) or a pair of wire electrodes (30) placed a certain distance apart on the skin, were shown to be effective in rodents. In large mammals such as pigs, dogs or humans the increased resistance of the skin, the thickness of the subcutaneous fat tissue, and the concern for tissue damage if the intensity of the electric field would be proportionally increased makes the plate and wire electrodes inefficient and impractical.
Pig or dog muscle fibers are quite large (31, 32) and consequently more suitable than rodent muscle for electro-permeabilization. Groups of hybrid pigs (weight 60-82 kg) were injected with 0.5 mg pSP-SEAP. The injection was followed in all cases by electroporation with needle electrodes. The experiment was repeated two times. One group received naked plasmid; the second group received plasmid + 0.01 mg/mL PLG, the formulation determined to be optimum in previous experiments. Pigs were weighed and serum was collected by jugular puncture before plasmid injection and at 2, 5, 8, 10 and 12 days post-injection. SEAP assay ( Figure  4A ) showed an increased expression in animals injected with 0.01 mg/mL PLG-coated plasmid versus naked plasmid throughout 12 days of the experiment. The values in pigs A. Serum SEAP expression in pigs injected with either a naked SEAPexpressing plasmid, or the same DNA formulated in 0.01 mg/mL PLG, to up to 12 days post-injection. Graph depicts mean values for the total number of animals included in experiments ± standard error of the mean. When PLG data was compared to plasmid only data through the entire experiment by ANOVA, *p < 0.02. B. Serum SEAP expression in dogs injected with either a naked SEAP-expressing plasmid, or the same DNA formulated in 0.01 mg/mL PLG, to up to 10 days post-injection. Graph depicts mean values for the total number of animals included in experiments ± standard error of the mean. When PLG data was compared by ANOVA to plasmid-only data throughout the entire experiment *p < 0.04. The abbreviations in the figure are: 0.5 mg/N is 0.5 mg pSP-SEAP in water, 0.1 mg/N is 0.1 mg pSP-SEAP in water, 0.5 mg/PLG is 0.5 mg pSP-SEAP formulated with 0.01 mg/mL PLG, and 0.1 mg/PLG is 0.1 mg pSP-SEAP formulated with 0.01 mg/mL PLG.
using the PLG-plasmid formulation were 32.9±19.3 ng/mL/kg compared to 17.14±12.44 ng/mL/kg in animals injected with naked plasmid (p<0.02).
To test the hypothesis that expression in large mammals is not species specific, similar experiments were conducted in dogs. Four groups of 5 dogs (weight range 7.9-14.8 kg, weight average 10.08 kg) were injected with plasmid pSP-SEAP. The injection was followed by electroporation using internal needle electrodes. Dogs received either 0.1 or 0.5 mg plasmid. Plasmid was either naked or coated with a 0.01 mg/mL dilution of PLG. Dogs were weighed and bled at baseline and days 3, 6, and 10 post-injection. Serum was assayed for SEAP. Values were corrected for weight using estimated blood volume. Without the facilitating agent, serum SEAP values were similar in dogs treated with 0.1 or 0.5 mg pSP-SEAP, suggesting plasmid uptake saturation ( Figure 4B ). PLG formulation increased SEAP expression 4-10 fold in injected dogs at 10 days post-treatment. The values for the formulated PLG plasmid were 143.6±95 ng/mL/kg versus 12.9±3.2 ng/mL/kg for animals injected with 0.5 mg naked plasmid (p<0.04). Moreover, serum SEAP values were 3-fold higher (57.7±32.2 ng/mL/kg) than those obtained in dogs treated with 0.1 mg of SEAP-expressing plasmid (p<0.04). These results suggest that during the electroporation process, PLG may enhance the plasmid uptake process. Several possible mechanisms may contribute: i) binding of PLG to surface proteins facilitates the uptake of plasmid by increasing its bioavailability and neutralizing the normal plasmid degradation process in the interstitial fluid, and ii) binding of PLG also protects the DNA from the nucleases present in the interstitial fluid. Intracellularly, PLG may prevent transport of DNA into the lysosomes by disruption of microtubule assembly (33, 34).
We have corroborated the finding that an anionic formulation of plasmid with PLG enhances expression in mice, pigs and dogs. Furthermore, this technique reduces any damage to the tissue caused by electroporation. In order for gene therapies to be transferred to large mammals, and ultimately to humans, it is imperative that extremely low quantities of plasmid are used, and that the transgene product is efficiently secreted from the skeletal muscle, detected and active. We have shown in our experiments that as little as 0.1 mg of plasmid delivered under the proper electroporation conditions can accomplish these requirements in large mammals. This plasmid quantity is 100 fold lower than the anticipated dose from direct extrapolation of the dose used in rodents (an average of 1 mg/kg). We predict that these improvements to the electroporation methodology in a large animal model constitute a step forward to a human therapy to deliver hormones, enzymes or cytokines, eliminating the need for viral vectors or liposomes, which can be antigenic when they are used as gene therapy vectors.
